Quantcast

Latest Amgen Inc. Stories

2010-02-16 10:54:00

SILVER SPRING, Md., Feb 16 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy. (Logo:...

2010-02-16 08:50:00

THOUSAND OAKS, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa). The FDA has determined that a REMS is...

2010-01-26 08:31:00

CHICAGO, Jan. 26 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for MA, AMGN, APA, NSC, and SYMC. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/012610B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: MasterCard Incorporated (NYSE: MA), Amgen Inc. (Nasdaq: AMGN), Apache Corp. (NYSE: APA), Norfolk Southern Corp. (NYSE: NSC), and...

2010-01-25 15:07:00

THOUSAND OAKS, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.05 for the fourth quarter of 2009, a decrease of 1 percent compared to $1.06 for the fourth quarter of 2008. Adjusted net income decreased 5 percent to $1,065 million in the fourth quarter of 2009 compared to $1,124 million in the fourth quarter of 2008. Full year 2009 adjusted EPS were $4.91 versus $4.55 in 2008, an 8 percent increase. Full year 2009...

2009-12-18 06:06:00

THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased...

2009-12-14 17:15:00

BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) and Amgen Inc.(Nasdaq: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes. Under the terms of the agreement, Array will receive an upfront payment of $60 million and...

2009-12-10 12:30:00

An estimated 70 to 80 percent of patients with advanced or stage four breast cancer develop bone metastases. Bone metastases occurs when the disease progresses to a patient's bones. When cancer spreads to the bone, it can make the bones weaker resulting in skeletal complications like fractures. Results of a new treatment option for the treatment of bone metastases in patients with advanced breast cancer was recently presented at the 2009 San Antonio Breast Cancer Symposium (SABCS) in...

2009-12-07 16:36:00

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The data were presented as an oral presentation at the 2009...

2009-12-06 12:21:00

NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS). MDS is a pre-leukemic condition in which early blood forming cells in the bone marrow are unable to mature normally, thereby limiting their ability to produce normal mature blood elements, which can lead to low platelet counts. The results of the...

2009-12-01 18:23:00

NEW YORK, Dec. 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis http://www.reportlinker.com/p0166816/The-Future-of-Monoclonal-Antibodies---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html Summary The author has released its latest research "The Future of...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related